A 67% objective response rate (ORR) is reported in the publication summarizing results from the Phase 1 study assessing Evaxion’s...
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or...
mRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-19 compared to...
Majority of patients continue to be followed for survival with multiple patients approaching 3 years Median Overall Survival (mOS) remains...
Velocity President and Chief Executive, Dr Paul Evans Velocity President and Chief Executive, Dr Paul Evans DURHAM, N.C., June 12,...
Clinical trial to evaluate the safety and efficacy of OBI-992 in advanced solid tumors.TAIPEI, Taiwan, June 12, 2024 (GLOBE NEWSWIRE)...
TORONTO, ON / ACCESSWIRE / June 10, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
mRNA-1083 met its primary endpoints, eliciting higher immune responses against influenza virus and SARS-CoV-2 than licensed flu and COVID vaccines...
Vancouver, British Columbia--(Newsfile Corp. - June 10, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or...
Manufacturing is underway and doses of Moderna's Spikevax 2024-2025 formula will be ready to ship as early as August, pending...
Independent health agency continues to attract industry’s brightest minds; fortifies teams companywide as part of commitment to delivering industry-leading innovation,...
Manufacturing of instruments, consumables and reagents for cell and protein analysisConsolidation of existing sites and functions in Ann ArborOverall investment...
Center for Biologics Evaluation and Research has chosen mRNA-3705 as one of four investigational medicines for accelerated development to address...
Company expects to lock database in June andremains on track to report key outcomes later in July. Pepinemab targets astrocyte...
Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or...
Helping pharmacies deliver smart patient messaging while giving time back to pharmacists WOBURN, Mass., June 5, 2024 /PRNewswire/ -- MedAdvisor Solutions,...
DNA vaccine proof-of-concept study expected to demonstrate an “mRNA better” platform LAWRENCEVILLE, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- IMUNON,...
TORONTO, ON / ACCESSWIRE / June 4, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to...
At a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced...